Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Heska Co. stock logo
HSKA
Heska
$119.99
$119.09
$57.83
$120.03
$1.31B1.58241,932 shsN/A
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
$546.31
+0.7%
$510.63
$356.14
$548.54
$43.99B1.54645,880 shs339,027 shs
Immunomedics, Inc. stock logo
IMMU
Immunomedics
$87.86
$87.41
$8.80
$87.93
$20.31B2.94.01 million shsN/A
Meridian Bioscience, Inc. stock logo
VIVO
Meridian Bioscience
$33.97
$33.70
$20.35
$34.38
$1.50B0.23973,737 shsN/A
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Heska Co. stock logo
HSKA
Heska
0.00%0.00%0.00%0.00%0.00%
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
0.00%+2.82%+4.09%+38.75%+14.41%
Immunomedics, Inc. stock logo
IMMU
Immunomedics
0.00%0.00%0.00%0.00%0.00%
Meridian Bioscience, Inc. stock logo
VIVO
Meridian Bioscience
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Heska Co. stock logo
HSKA
Heska
N/AN/AN/AN/AN/AN/AN/AN/A
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
3.862 of 5 stars
1.44.00.03.73.52.51.3
Immunomedics, Inc. stock logo
IMMU
Immunomedics
N/AN/AN/AN/AN/AN/AN/AN/A
Meridian Bioscience, Inc. stock logo
VIVO
Meridian Bioscience
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Heska Co. stock logo
HSKA
Heska
0.00
N/AN/AN/A
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
2.80
Moderate Buy$558.112.16% Upside
Immunomedics, Inc. stock logo
IMMU
Immunomedics
0.00
N/AN/AN/A
Meridian Bioscience, Inc. stock logo
VIVO
Meridian Bioscience
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest IDXX, IMMU, VIVO, and HSKA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/2/2025
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetHold ➝ Hold$510.00 ➝ $540.00
7/1/2025
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$625.00
6/11/2025
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$515.00 ➝ $580.00
5/19/2025
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetHold ➝ Hold$460.00 ➝ $510.00
5/5/2025
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$548.00 ➝ $558.00
4/14/2025
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetHold ➝ Hold$450.00 ➝ $420.00
(Data available from 7/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Heska Co. stock logo
HSKA
Heska
$257.31M5.09$1.69 per share70.99$39.00 per share3.08
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
$3.90B11.27$12.41 per share44.01$19.48 per share28.04
Immunomedics, Inc. stock logo
IMMU
Immunomedics
$290K70,028.66N/AN/A$1.38 per share63.67
Meridian Bioscience, Inc. stock logo
VIVO
Meridian Bioscience
$333.02M4.49$1.78 per share19.13$8.41 per share4.04
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Heska Co. stock logo
HSKA
Heska
-$19.89M-$1.93N/A83.33N/A-7.86%0.94%0.67%N/A
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
$887.87M$10.8250.4940.233.9922.76%57.35%26.97%8/4/2025 (Confirmed)
Immunomedics, Inc. stock logo
IMMU
Immunomedics
-$357.19M-$1.84N/AN/AN/AN/A-132.40%-51.32%N/A
Meridian Bioscience, Inc. stock logo
VIVO
Meridian Bioscience
$42.46M$0.9735.02N/A12.70%16.74%13.09%N/A

Latest IDXX, IMMU, VIVO, and HSKA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/1/2025Q1 2025
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
$2.93$2.96+$0.03$2.96$998.25 million$998.43 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Heska Co. stock logo
HSKA
Heska
N/AN/AN/AN/AN/A
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
N/AN/AN/AN/AN/A
Immunomedics, Inc. stock logo
IMMU
Immunomedics
N/AN/AN/AN/AN/A
Meridian Bioscience, Inc. stock logo
VIVO
Meridian Bioscience
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Heska Co. stock logo
HSKA
Heska
0.23
5.64
4.12
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
0.31
1.16
0.81
Immunomedics, Inc. stock logo
IMMU
Immunomedics
N/A
12.84
12.58
Meridian Bioscience, Inc. stock logo
VIVO
Meridian Bioscience
0.07
3.63
2.46

Institutional Ownership

CompanyInstitutional Ownership
Heska Co. stock logo
HSKA
Heska
99.01%
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
87.84%
Immunomedics, Inc. stock logo
IMMU
Immunomedics
88.89%
Meridian Bioscience, Inc. stock logo
VIVO
Meridian Bioscience
89.72%

Insider Ownership

CompanyInsider Ownership
Heska Co. stock logo
HSKA
Heska
12.30%
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
0.98%
Immunomedics, Inc. stock logo
IMMU
Immunomedics
12.00%
Meridian Bioscience, Inc. stock logo
VIVO
Meridian Bioscience
2.30%
CompanyEmployeesShares OutstandingFree FloatOptionable
Heska Co. stock logo
HSKA
Heska
80810.91 million9.57 millionNot Optionable
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
11,00080.42 million79.63 millionOptionable
Immunomedics, Inc. stock logo
IMMU
Immunomedics
366231.14 millionN/AOptionable
Meridian Bioscience, Inc. stock logo
VIVO
Meridian Bioscience
70244.01 million43.00 millionOptionable

Recent News About These Companies

Meridian Bioscience Inc (VIVO)
India's smartphone mkt grows 6%, Vivo tops
Precision BioSciences Launches First Hepatitis B Gene-Editing Trial
Meridian Growth Legacy MERDX
Biomerica, Inc. (BMRA)

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Heska stock logo

Heska NASDAQ:HSKA

Heska Corporation manufactures and sells diagnostic and specialty products and solutions for veterinary practitioners in the United States, Canada, Mexico, Germany, Italy, Spain, France, Switzerland, Australia, and Malaysia. The company offers Element DC, Element DCX, Element DC5x veterinary chemistry analyzers for blood chemistry and electrolyte analysis; Element RC, Element RCX, and Element RC3X chemistry systems for blood chemistry and electrolyte analysis; Element HT5 and scil Vet abc Plus veterinary hematology analyzers to measure blood cell, platelet count, and hemoglobin levels; Element POC blood gas and electrolyte analyzers; Element i immunodiagnostic analyzers; and Element COAG and Element AIM veterinary analyzers. It also provides HeskaView Telecytology that provides in-clinic automated microscopic slide scanning and computing equipment; IV infusion pumps; digital radiography hardware and mobile digital radiography products; ultrasound systems; Cloudbank, a Web-based image storage solution; point-of-care products to detect antigens and antibodies associated with infectious and parasitic diseases of animals; Tri-Heart Plus chewable tablets for the treatment of canine heartworm infection, and ascarid and hookworm infections; and allergy products and services, including ALLERCEPT definitive allergen panels and therapy shots or drops. In addition, the company provides a line of bovine vaccines; biological and pharmaceutical products to other animal health companies; turnkey services comprising research, licensing, production, labeling, and packaging; and validation support and distribution services. It sells its products to veterinarians through a telephone sales force and third-party distributors; and trade shows, print advertising, and other distribution relationships. The company was formerly known as Paravax, Inc. and changed its name to Heska Corporation in 1995. The company was incorporated in 1988 and is based in Loveland, Colorado.

IDEXX Laboratories stock logo

IDEXX Laboratories NASDAQ:IDXX

$546.31 +3.60 (+0.66%)
Closing price 07/3/2025 03:58 PM Eastern
Extended Trading
$546.31 0.00 (0.00%)
As of 07/3/2025 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

IDEXX Laboratories, Inc. develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. It also provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory diagnostic instruments, and services for biomedical research community. In addition, the company offers diagnostic and health-monitoring products for livestock, poultry, and dairy; products that test water for various microbiological contaminants; point-of-care electrolytes and blood gas analyzers; in-clinic chemistry, blood and urine chemistry, hematology, immunoassay, urinalysis, and coagulation analyzers; and SNAP rapid assays test kits. Further, it provides Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, and Quanti-Tray products; and veterinary software and services for independent veterinary clinics and corporate groups. Additionally, the company offers human medical point-of-care products and laboratory diagnostics services. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.

Immunomedics stock logo

Immunomedics NASDAQ:IMMU

Immunomedics, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibody-based products for the targeted treatment of cancer. It develops sacituzumab govitecan, an antibody-drug conjugate for the treatment of patients with metastatic triple-negative breast cancer. The company focuses on commercializing sacituzumab govitecan as a third-line therapy for patients with metastatic triple-negative breast cancer in the United States. The company also develops IMMU-140 for treatment of hematologic malignancies; and IMMU-130 to treat Colorectal cancer. Its other product candidates includes epratuzumab, an anti-CD22 antibody; veltuzumab, an anti-CD20 antibody; milatuzumab, an anti-CD74 antibody; and IMMU-114, a HLA-DR antibody. Immunomedics, Inc. has clinical collaboration with AstraZeneca and MedImmune to evaluate Imfinzi, a human monoclonal antibody against PD-L1, with sacituzumab govitecan as a frontline treatment of patients with TNBC and urothelial cancer; collaboration agreement with GBG Forschungs GmbH to develop sacituzumab govitecan for the treatment of breast cancer; and clinical collaboration with F. Hoffman-La Roche Ltd to treat patients with metastatic or inoperable locally advanced TNBC versus atezolizumab plus nab-paclitaxel as standard of care. The company was founded in 1982 and is headquartered in Morris Plains, New Jersey. As of October 23, 2020, Immunomedics, Inc. operates as a subsidiary of Gilead Sciences, Inc.

Meridian Bioscience stock logo

Meridian Bioscience NASDAQ:VIVO

Meridian Bioscience, Inc. engages in the development, production, sale, and distribution of diagnostic products. Its platforms include molecular, immunoassay, urea breath, and blood chemistry. It operates through the Diagnostics and Life Science segments. The Diagnostics segment consists of manufacturing operations for infectious disease and blood chemistry products and the sale and distribution of diagnostics products domestically and abroad. The Life Science segment distributes bulk antigens, antibodies, polymerase chain reaction/ quantitative PCR reagents, nucleotides, competent cells, and bioresearch reagents used by researchers, agri-bio companies, and other diagnostic manufacturing companies. The company was founded by William J. Motto in 1976 and is headquartered in Cincinnati, OH.